ORAGENICS INC (OGEN)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$0.51+2.31%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OGEN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -50.9% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
OGEN — legal / regulatory event — NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDAR…
Dated 2026-08-28
NOTICE OF DELISTING OR FAILURE TO SATISFY A CONTINUED LISTING RULE OR STANDARD; TRANSFER OF LISTING. On August 26, 2026, Oragenics, Inc. (the “ Company ”) received notification (the “ Notice ”) from the NYSE American LLC (the “ NYSE American ”) that the Company is no longer in compliance with NYSE American’s continued listing standards. Specifically, the letter states that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii)…
Why it matters: Smaller operating losses are important for financial health. They show that management controls costs.
Supportive ifOperating losses decrease from -$2.2M in Q1 2026 to less than -$2.0M in Q2 2026.
Worry ifOperating losses remain at or worsen from -$2.2M in Q2 2026.
Why it matters: Progress updates will show how well the trial is going and if the treatment is effective.
Watch forManagement shares good results or milestones from the Phase IIa trial.
Also watch forNegative trial results or delays in patient enrollment or dosing.
Why it matters: Completing this agreement would improve Oragenics' TBI treatment. It shows they care about TBI care.
Supportive ifA final agreement for the CardioDialysis license will be signed in 90 days.
Worry ifNo agreement is reached, or the timeline extends beyond the 90-day target.
Why it matters: The new CFO may improve money management. They could also make better plans.
Supportive ifManagement shares better financial numbers or plans with the new CFO.
Worry ifNo clear signs of better financial results or direction with the new CFO.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$151 on $10,000 · ±1.5% | How much price usually moves either way. |
| Bad day | $782 loss on $10,000 · 7.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,548 loss on $10,000 · 65.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A new CFO can change financial management and strategy. This could affect cash flow and costs.
Watch forThere are positive changes in cash flow after John Spencer's appointment.
Also watch forThere are no clear signs of better financial management. Losses keep happening after the new appointment.
Why it matters: High enrollment shows there is a need for new concussion treatments. It shows urgent medical needs.
Supportive ifAt least two new clinical trial sites in Australia will start enrolling patients by Q3 2026.
Worry ifNo new sites are activated, or enrollment remains stagnant at the current site.
Why it matters: Keeping financial control is key for the company. It affects cash flow and operations.
Worry ifOperating losses drop a lot. This shows better cash flow management.
Less concerning ifOperating losses stay high or get worse. This shows poor financial control.
Why it matters: A shift in revenue growth could signal a change in company momentum. This is important as the sector is maturing.
Supportive ifRevenue growth is speeding up again. It is now above 9%, close to its past highs.
Worry ifRevenue growth continues to decelerate or stays below 9%.
Why it matters: The compliance plan is important. It helps avoid being removed from NYSE American.
Worry ifOragenics will send a compliance plan to NYSE American by 45 days after August 26, 2026.
Less concerning ifThe compliance plan is not submitted by the deadline, risking delisting.
Why it matters: High enrollment shows demand for ONP-002. This helps with future funding and development.
Supportive ifEnrollment reaches 20 participants in the Phase IIa trial by the end of Q4 2026.
Worry ifEnrollment stalls below 10 participants by the end of Q4 2026.
Why it matters: The FDA's feedback is critical for advancing ONP-002 to the next trial phase.
Supportive ifFDA gives a positive response to the IND application by the end of Q4 2026.
Worry ifFDA response shows big concerns or delays about the IND application.